Published in Radiology on July 25, 2011
CT perfusion of the liver: principles and applications in oncology. Radiology (2014) 0.92
DCE-MRI of the liver: effect of linear and nonlinear conversions on hepatic perfusion quantification and reproducibility. J Magn Reson Imaging (2013) 0.88
Intraprocedural blood volume measurement using C-arm CT as a predictor for treatment response of malignant liver tumours undergoing repetitive transarterial chemoembolization (TACE). Eur Radiol (2015) 0.84
Computed Tomography (CT) Perfusion in Abdominal Cancer: Technical Aspects. Diagnostics (Basel) (2013) 0.83
Quantitative characterization of hepatocellular carcinoma and metastatic liver tumor by CT perfusion. Cancer Imaging (2013) 0.83
Effect of sampling frequency on perfusion values in perfusion CT of lung tumors. AJR Am J Roentgenol (2013) 0.82
Effect of dual vascular input functions on CT perfusion parameter values and reproducibility in liver tumors and normal liver. J Comput Assist Tomogr (2012) 0.79
Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol (2015) 0.78
CTA combined with CT perfusion for assessing the efficacy of anti-angiogenic therapy in rabbit VX2 tumors. Acad Radiol (2012) 0.77
Preoperative hepatic CT perfusion as an early predictor for the recurrence of esophageal squamous cell carcinoma: initial clinical results. Oncol Rep (2014) 0.76
Three-dimensional whole-liver perfusion magnetic resonance imaging in patients with hepatocellular carcinomas and colorectal hepatic metastases. BMC Gastroenterol (2013) 0.76
New approaches for precise response evaluation in hepatocellular carcinoma. World J Gastroenterol (2014) 0.76
Reproducibility and variability of very low dose hepatic perfusion CT in metastatic liver disease. Diagn Interv Radiol (2016) 0.75
CT Perfusion Imaging Can Predict Patients' Survival and Early Response to Transarterial Chemo-Lipiodol Infusion for Liver Metastases from Colorectal Cancers. Korean J Radiol (2015) 0.75
Dysfunctional microcirculation of the lumbar vertebral marrow prior to the bone loss and intervertebral discal degeneration. Spine (Phila Pa 1976) (2015) 0.75
A Bayesian Nonparametric Approach for Functional Data Classification with Application to Hepatic Tissue Characterization. Cancer Inform (2016) 0.75
Imaging for assessment of treatment response in hepatocellular carcinoma: Current update. Indian J Radiol Imaging (2015) 0.75
A semi-automatic method for the extraction of the portal venous input function in quantitative dynamic contrast-enhanced CT of the liver. Br J Radiol (2017) 0.75
Statistical methods for assessing agreement between two methods of clinical measurement. Lancet (1986) 211.50
Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 17.03
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol (2004) 3.38
Measurement error proportional to the mean. BMJ (1996) 3.34
Perfusion CT: a worthwhile enhancement? Br J Radiol (2003) 2.79
Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed (2002) 2.24
Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. Radiology (2006) 1.91
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol (2003) 1.88
Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. Radiology (2007) 1.87
Reproducibility of quantitative CT perfusion imaging. Br J Radiol (2001) 1.76
Correlation between hepatic tumor blood flow and glucose utilization in a rabbit liver tumor model. Radiology (2006) 1.68
Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am (2009) 1.67
A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps. AJNR Am J Neuroradiol (2000) 1.61
Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy. AJNR Am J Neuroradiol (2006) 1.27
Quantitative colorectal cancer perfusion measurement using dynamic contrast-enhanced multidetector-row computed tomography: effect of acquisition time and implications for protocols. J Comput Assist Tomogr (2005) 1.24
Hepatic perfusion in a tumor model using DCE-CT: an accuracy and precision study. Phys Med Biol (2008) 1.16
Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumour. Phys Med Biol (2001) 1.11
Quantitative assessment of tissue perfusion using MDCT: comparison of colorectal cancer and skeletal muscle measurement reproducibility. AJR Am J Roentgenol (2006) 0.94
The calpain system. Physiol Rev (2003) 9.95
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell (2008) 4.63
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 4.34
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Metastatic patterns in adenocarcinoma. Cancer (2006) 4.16
Glutamate receptor exocytosis and spine enlargement during chemically induced long-term potentiation. J Neurosci (2006) 3.84
Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol (2007) 3.45
Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol (2011) 3.19
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Genetic identification of an On-Off direction-selective retinal ganglion cell subtype reveals a layer-specific subcortical map of posterior motion. Neuron (2009) 3.13
Cancer: the road to Amiens. J Clin Oncol (2008) 3.10
Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86
Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol (2003) 2.83
Epstein-Barr virus and cancer. Clin Cancer Res (2004) 2.78
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 2.77
DSCAM and DSCAML1 function in self-avoidance in multiple cell types in the developing mouse retina. Neuron (2009) 2.73
Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer (2007) 2.62
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Reductive evolution suggested from the complete genome sequence of a plant-pathogenic phytoplasma. Nat Genet (2003) 2.55
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53
Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer (2005) 2.49
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol (2012) 2.48
Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet (2011) 2.48
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity (2013) 2.37
SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity (2004) 2.30
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res (2012) 2.27
Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol (2010) 2.26
Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res (2003) 2.25
Design and Integration of a Telerobotic System for Minimally Invasive Surgery of the Throat. Int J Rob Res (2009) 2.18
Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol (2010) 2.16
Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol (2012) 2.09
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol (2012) 2.04
Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer (2004) 2.02
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer (2012) 2.01
Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl Med Biol (2006) 1.98
Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther (2008) 1.92
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther (2008) 1.88
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol (2009) 1.84
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res (2012) 1.83
Mussel protein adhesion depends on interprotein thiol-mediated redox modulation. Nat Chem Biol (2011) 1.82
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One (2011) 1.80
SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol (2007) 1.79
Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles. Biomacromolecules (2011) 1.79
Transgenic mice reveal unexpected diversity of on-off direction-selective retinal ganglion cell subtypes and brain structures involved in motion processing. J Neurosci (2011) 1.77
Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells. Proc Natl Acad Sci U S A (2011) 1.76
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res (2011) 1.71
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res (2012) 1.70
The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife (2012) 1.69
Sarcoidosis and malignancy. Clin Dermatol (2007) 1.67
Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol (2014) 1.67
Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. Mol Imaging (2004) 1.64
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer (2004) 1.62
Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol (2011) 1.58
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood (2004) 1.58
The role of investigational therapy in management of patients with advanced metastatic malignancy. J Clin Oncol (2008) 1.57
Differential effects of pyrrolidine dithiocarbamate on TNF-alpha-mediated liver injury in two different models of fulminant hepatitis. J Hepatol (2008) 1.55
Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology (2005) 1.55
Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma (2006) 1.55
Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol (2011) 1.54
Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics (2006) 1.54
Overexpression of miR-708 and its targets in the childhood common precursor B-cell ALL. Pediatr Blood Cancer (2013) 1.54
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol (2010) 1.53
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol (2006) 1.52
Structural insight into dGTP-dependent activation of tetrameric SAMHD1 deoxynucleoside triphosphate triphosphohydrolase. Nat Commun (2013) 1.50
Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology (2012) 1.50
Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology (2011) 1.50
Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res (2007) 1.49
The changes of pulmonary blood flow in non-ventilated lung during one lung ventilation. J Clin Monit Comput (2010) 1.49
Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol (2007) 1.48
Soybean NAC transcription factors promote abiotic stress tolerance and lateral root formation in transgenic plants. Plant J (2011) 1.48
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res (2011) 1.48
Imaging in the diagnosis, staging, and follow-up of colorectal cancer. AJR Am J Roentgenol (2002) 1.47
Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. Clin Cancer Res (2011) 1.46
The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci (2005) 1.46
Morphologic classification of microvessels in hepatocellular carcinoma is associated with the prognosis after resection. J Gastroenterol Hepatol (2011) 1.45
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood (2002) 1.45
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther (2006) 1.45
TAK1 is required for the survival of hematopoietic cells and hepatocytes in mice. J Exp Med (2008) 1.45
Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys (2002) 1.44
Uropygial gland-secreted alkanols contribute to olfactory sex signals in budgerigars. Chem Senses (2010) 1.44
A novel mutation within the 2B rod domain of keratin 9 in a Chinese pedigree with epidermolytic palmoplantar keratoderma combined with knuckle pads and camptodactyly. Eur J Dermatol (2011) 1.44
Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer (2010) 1.44
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2012) 1.43
Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure. Leuk Lymphoma (2014) 1.42
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer (2009) 1.42
Involvement of the prostaglandin E receptor EP2 in paeoniflorin-induced human hepatoma cell apoptosis. Anticancer Drugs (2013) 1.42
Application of biologically based computer modeling to simple or complex mixtures. Environ Health Perspect (2002) 1.42
Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol (2006) 1.41
Effects of interfacial redox in mussel adhesive protein films on mica. Adv Mater (2011) 1.41
Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model. Cancer Biol Ther (2009) 1.41